Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SBP 002

X
Drug Profile

SBP 002

Alternative Names: Coramsine; SBP 002 cream - Solbec; SBP002; Solasonine/solamargine

Latest Information Update: 12 Nov 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solbec Pharmaceuticals
  • Developer Freedom Eye
  • Class Antineoplastics; Immunotherapies; Skin disorder therapies; Solanaceous alkaloids
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Renal cancer

Highest Development Phases

  • No development reported Psoriasis; Renal cancer; Solid tumours

Most Recent Events

  • 05 Dec 2008 Solbec is now called Freedom Eye Limited
  • 19 May 2008 SBP 002 is available for licensing worldwide (http://www.solbec.com.au)
  • 04 Feb 2008 Use of SBP 002 for the single use treatment of a US patient with advanced RCC has been discontinued

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top